With the advent of GLP-1 drugs, perspectives about weight management are changing. Ted Kyle hopes the food industry can make some changes, too, to better serve all consumers.
Separate fact from fiction on obesity with expert insights! Debunk common myths and discover the truth about this complex ...
Novo Nordisk on Monday revealed data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares ...
The prevalence of obesity and diabetes has grown worldwide, presenting notable challenges to public health and health care ...
By 2050, over half of the adults and one third of the youth may be obese. Experts have called for urgent action to prevent ...
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
The demand for glucagon-like peptide 1 (GLP-1) receptor agonists for overweight/obesity has created a clinical conundrum for ...
GLP-1RA discontinuation and lack of reinitiation was more common among patients with obesity and without type 2 diabetes than with type 2 diabetes.
Public health officials warned that Czech guidelines, outdated by 20 years, must align with countries worldwide to prioritize ...
Event summary produced by The Globe and Mail Events team. The Globe’s editorial department was not involved.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback